Content options
The new melanoma vaccine does not stop healthy people from getting skin cancer. It is a treatment for people who have already had melanoma removed, and it is designed to lower the chance that the cancer comes back. According to reports, including a Washington Post headline, it cut that risk by almost half, but "half" describes a relative change, not the share of patients who were spared.
Below we explain how the vaccine works, what the number means in plain arithmetic, who could benefit first, and why sunscreen and shade still matter more for most of us.
Key takeaways
- The vaccine is a therapy for people treated for melanoma, not a shot to prevent skin cancer in the general public.
- It works by teaching the immune system to recognise features of a patient's own tumour and attack leftover cancer cells.
- "Almost half" is a relative risk reduction. The real-world benefit depends on how likely the cancer was to return in the first place.
- Sun protection remains the main prevention tool, and approval and availability of the vaccine are still some way off for most countries.
What exactly is this melanoma vaccine?
Melanoma is the most dangerous form of skin cancer because it can spread to other organs. Surgery works well when it is caught early. The worry for doctors is that some cancer cells may be left behind or already travelling, and they can cause a relapse months or years later.
The vaccines in the news belong to a group called personalised cancer vaccines. As reported for the leading candidate, this approach uses mRNA technology, the same family of tools used in some COVID-19 vaccines. It is given alongside an existing immunotherapy drug, pembrolizumab (sold as Keytruda), rather than on its own.
The word "vaccine" is slightly misleading here. Classic vaccines such as measles or HPV prevent infection in healthy people. A cancer vaccine of this type is a treatment that uses the same immune-training idea against a disease that already exists.
How does a skin cancer vaccine train the immune system?
Every tumour carries random genetic errors. Some of these errors produce odd protein fragments that normal cells do not have. The immune system can see such fragments as foreign, but tumours often hide or switch off the alarm. The vaccine tries to put that alarm back on.
- Sample the tumour. Surgeons remove the melanoma, and a piece of tissue is sent for genetic sequencing, alongside a sample of healthy tissue for comparison.
- Find the differences. Software compares the two and picks out the mutations most likely to be recognised by immune cells. These are called neoantigens.
- Build a custom vaccine. A set of instructions for those neoantigens is manufactured as mRNA, unique to that patient.
- Inject and train. After the shot, the body's cells read the instructions and display the fragments. T cells, the immune system's targeted fighters, learn what to look for.
- Release the brakes. The companion drug blocks a protein called PD-1 that tumours use to calm T cells, so the trained cells can act.
The result, in theory, is an immune system that hunts for the specific signature of this patient's cancer anywhere in the body. That is also why the process takes weeks and why each dose is made individually.
Does a cancer vaccine prevent skin cancer?
No. This is the most common misunderstanding in the headlines. The table separates what the vaccine does from what people often assume.
| Common assumption | What is actually the case |
|---|---|
| It stops healthy people getting melanoma | It is tested in patients whose melanoma was already removed |
| It is a one-size-fits-all shot | Each dose is made from the individual patient's tumour |
| It replaces other treatment | In the reported trials it is added to an existing immunotherapy drug |
| It protects you from sun damage | It does nothing to prevent UV damage to skin cells |
What does "cut risk by almost half" mean in real numbers?
This is where headlines can mislead. A relative risk reduction tells you the proportion by which risk falls. An absolute risk reduction tells you how many more people actually stay well. You need both to judge a treatment.
Let us use a made-up example, not trial data. Say 100 patients have a 40% chance of the melanoma returning within three years without the vaccine, so 40 of them relapse.
- A 49% relative reduction means the risk shrinks by 49% of 40, which is 40 × 0.49 ≈ 19.6.
- About 20 patients relapse instead of 40.
- The absolute reduction is roughly 20 percentage points, so around 1 in 5 patients gains a relapse-free outcome. Put another way, about 5 people need treatment for one extra person to benefit (100 ÷ 19.6 ≈ 5).
Now change the starting point. Suppose a different group has only a 2% chance of recurrence, so 2 in 100 relapse. A 49% cut brings that to about 1 in 100. The relative figure is identical, but only one person in 100 benefits.
The lesson is that "almost half" is impressive when the starting risk is high, and far less dramatic when it is low. Published results for this vaccine class came from patients at high risk of recurrence (stage III or IV melanoma after surgery), which is where the benefit looks largest. For the exact reported figures, look at the published trial paper or the company's announcement, not just the headline.
Who could benefit first?
If the vaccine is approved, the first candidates will almost certainly be people who have had melanoma removed and whose doctors judge them to be at meaningful risk of relapse. That generally means cancers that had grown deeper or reached lymph nodes.
People with very early, thin melanomas, which surgery cures in the vast majority of cases, are less likely to need it. For them the extra treatment, cost and side effects may not be worth a small absolute gain.
Side effects are part of the picture. Immunotherapy can cause fatigue and, in some people, immune reactions affecting organs such as the thyroid, gut or skin. Whether adding the vaccine changes that balance is a question the larger trials are meant to answer, and your oncologist is the right person to weigh it for you.
When will cancer vaccines be available?
Not yet for routine use. Promising results from a mid-stage trial are an important step, but regulators generally want confirmation from a larger phase 3 trial before approving a treatment. A phase 3 trial of this melanoma vaccine has been under way, with results expected in the coming years.
Even after approval, rollout would be gradual. Personalised manufacturing is slower and costlier than making a standard drug, and it would need regulatory clearance country by country. For patients in India, reaching the clinic is likely to take longer than in the US or Europe, and cost will be a major question. Anyone who has had melanoma and is curious can ask their oncologist whether a clinical trial is open to them, rather than waiting for approval.
Vaccine or sunscreen: which protects you better?
For almost everyone reading this, sun protection is the tool that matters. The two serve completely different people at different moments.
| Feature | Melanoma vaccine | Sun protection |
|---|---|---|
| Purpose | Lower the chance of relapse after treatment | Reduce the chance of skin damage and cancer in the first place |
| Who uses it | Patients treated for higher-risk melanoma | Everyone |
| Availability | Still in clinical trials | Available today |
| Cost | Expected to be high | Low |
| Evidence | Promising trial results, awaiting confirmation | Decades of evidence on UV and skin cancer |
Skin cancer prevention tips that actually work
- Seek shade between roughly 10 am and 4 pm, when UV is strongest.
- Use a broad-spectrum sunscreen of SPF 30 or higher and reapply about every two hours outdoors, and after swimming or heavy sweating.
- Wear a wide-brimmed hat, sunglasses that block UV, and covering clothing.
- Avoid sunbeds. They raise melanoma risk and have no health benefit.
- Check your skin monthly and see a doctor about any mole that changes in size, shape or colour, itches, bleeds or looks different from the others.
Heat and sun exposure often go together during extreme weather, as we saw in our report on the Europe heatwave. Staying well hydrated helps in the heat, but it is not a substitute for sunscreen or shade.
Is this relevant in India?
Melanoma is less common in India than in fair-skinned populations, because natural skin pigment gives some protection against UV. That does not make it irrelevant. Among Indian patients, a larger share of melanomas appear on the palms, soles and under the nails, called acral melanoma, which is not strongly linked to sun exposure. Most of the large vaccine trials have focused on cancers more common in Western populations, so researchers will need data on how well it works in other groups.
The practical advice is the same for everyone. A dark spot or streak under a nail, or a sore on the sole that does not heal, deserves a dermatologist's check rather than waiting and watching.
Common mistakes when reading cancer vaccine news
- Treating relative risk as the chance of cure. A 49% reduction is not a 49% chance of being protected.
- Assuming a mid-stage trial equals approval. Larger trials sometimes shrink or change the early picture.
- Dropping sun protection. The vaccine is not meant for prevention.
- Hunting for unproven "cancer vaccines" online. Clinics that sell unapproved shots are a risk. Trials are listed through official registries and hospitals.
More broadly, this fits a wider shift toward personalised medicine, one of the themes in our look at health trends for 2026.
FAQ
How does the skin cancer vaccine work in simple words?
Doctors read the genetic fingerprint of your tumour and make a vaccine that shows your immune cells those unusual markers. The immune system then learns to spot and destroy any remaining cancer cells carrying them.
Can healthy people get the melanoma vaccine to prevent skin cancer?
No. The trials tested people who had already had melanoma surgically removed. There is currently no vaccine that prevents melanoma in people who have never had it.
What is the difference between relative and absolute risk?
Relative risk shows the proportional change, such as a 49% drop. Absolute risk shows the actual difference in numbers, such as 40 in 100 falling to 20 in 100. The same relative drop can mean very different real benefits depending on the starting risk.
When will cancer vaccines be available to patients?
There is no confirmed date. Approval would normally depend on larger trials confirming the early results, followed by regulators in each country. Patients may be able to access it earlier through a clinical trial.
Is the vaccine safer than conventional treatment?
We do not yet know enough to say. It is given with an immunotherapy drug that can itself cause side effects, so safety is being measured as part of the trials. Your oncologist can explain the risks for your situation.
Bottom line
The vaccine is a real and promising advance for people at high risk of melanoma returning, but it is a treatment still moving through trials, not a shield for the public. Read "almost half" as a relative figure and ask for the absolute numbers. For now, shade, sunscreen and regular skin checks remain the steps that work for everyone, and anyone with a past melanoma should ask their oncologist about trials and follow-up.
